Edap Tms SA

Edap Tms SA(FOCL)股票分析

$4.340

+0.243 (+5.60%)收盘时

Loading chart…
最高
4.400
开盘
4.240
成交量加权均价
4.33
成交量
7.93K
市值
—
最低
4.240
成交额
34.31K
企业价值/息税折旧摊销前利润(TTM)
-5.24

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

AI 分析 of Edap Tms SA (FOCL)

买入

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

估值指标

Edap Tms SA(FOCL)当前预期市盈率为 38.91,5 年平均预期市盈率为 38.91。

预期市盈率

合理
5 年均值 P/E
38.91
当前P/E
38.91
高估
38.91
低估
38.91

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.00
当前EV/EBITDA
-5.24
高估
-4.78
低估
-7.22

预期市销率

合理
5 年均值 P/S
2.79
当前P/S
2.78
高估
3.04
低估
2.54

持有 FOCL 的大户

S

Soleus Capital Management, L.P.

+ 持有FOCL

-7.34%

3个月收益率

事件时间线

2026-08-14 (ET)

12:00:00

Major Averages Broadly Lower Near Noon

2026-08-13 (ET)

16:30:00

Company Announces ESWL and Distribution Segments as Discontinued Operations

16:30:00

FocalTherics Q2 Revenue at $13.2M, Below Expectations

2026-08-11 (ET)

21:30:00

TD Cowen and Mizuho Jointly Manage Offering

17:00:00

Sees Q2 Gross Margin at 54%-56%

资讯

FOCL 常见问题 —— 由 Alphio AI 解答

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector.

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易